Tommie Simon, MD
Rheumatology · Lawton, OKNPI 1043653264
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,210 of the $54,661 with a category attached, or 69.9%. AbbVie accounts for 67.7% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $34,766 and has fallen 99.7% since, to $116 in 2025. Among rheumatology clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 204 payments — averaging $267.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$37K
- Amgen$16K
- Johnson & Johnson$301
- GSK$217
- Janssen Scientific Affairs, LLC$215
- Novartis$215
- plus $1K from 10 others
What the payments were for
- Speaking & faculty fees$38,21070%
- Travel & lodging$10,92720%
- Food & beverage$5,30610%
- Education$2180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 83 | $36,996 |
| Amgen(2 entities) | 44 | $15,615 |
| Johnson & Johnson | 13 | $301 |
| GSK | 9 | $217 |
| Janssen Scientific Affairs, LLC | 4 | $215 |
| Novartis | 7 | $215 |
| Sanofi | 4 | $203 |
| UCB, Inc. | 9 | $197 |
| Lilly USA, LLC | 6 | $192 |
| AstraZeneca | 9 | $167 |
| Genentech USA, Inc. | 7 | $136 |
| E.r. Squibb & Sons, L.L.C. | 5 | $96 |
| Genentech, Inc. | 1 | $48 |
| Bristol Myers Squibb | 1 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$54,661 in reported general payments places this provider in the 90th percentile of 67 rheumatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 155 | $1,117,103 |
| Enbrel SureclickEtanercept | 57 | $436,341 |
| RinvoqUpadacitinib | 50 | $321,693 |
| Skyrizi PenRisankizumab-Rzaa | 11 | $226,762 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 16 | $132,948 |
| Taltz AutoinjectorIxekizumab | 14 | $99,914 |
| OtezlaApremilast | 16 | $87,924 |
| Hydroxychloroquine Sulfate | 361 | $15,930 |
| MethotrexateMethotrexate Sodium | 320 | $6,884 |
| Duloxetine Hcl | 335 | $6,776 |
| Leflunomide | 72 | $4,267 |
| Cevimeline Hcl | 20 | $3,017 |
| Mycophenolate Mofetil | 40 | $2,345 |
| Gabapentin | 179 | $2,197 |
| Sulfasalazine | 53 | $1,360 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $36,996 | $321,69350 claims |
| AmgenOtezla | $15,615 | $87,92416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 67 rheumatology providers in Oklahoma.
Other rheumatology in Lawton
- Joan MerrillOklahoma City$864K
- Latisha HeinlenOklahoma City$675K
- Debbie FoleyTulsa$281K
- Mohammad KhanOklahoma City$94K
- Cristina ArriensOklahoma City$82K
- Mary Hinojos MamutTulsa$21K
- Drew HuffmanMoore$20K
- Manuel CalvinTulsa$19K
- Amy ShultzDuncan$19K
- Alan MartinTulsa$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.